Aptinyx Investor Relations Material
Latest events
Q3 2022
Aptinyx
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Aptinyx Inc
Access all reports
Aptinyx Inc. is a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders with unmet medical need. The Company's two clinical programs include APTX101, which is being developed as a monotherapy for adults with refractory or high risk myoclonic seizures and adults with refractory partial onset seizures (ROS), and APTX102, which is being developed as a monotherapy for the treatment of adults with drug-resistant epilepsy (RxR-XII)
Latest articles
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Ticker symbol
Country
🇺🇸 United States